Diaceutics (LON:DXRX) Insider Sells £3,325,000 in Stock

Diaceutics PLC (LON:DXRX) insider Peter Keeling sold 1,750,000 shares of the company’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of GBX 190, for a total transaction of £3,325,000.

Diaceutics Price Performance

Shares of DXRX stock traded down GBX 1 during trading hours on Friday, hitting GBX 194. 330,586 shares of the company’s stock were exchanged, compared to its average volume of 298,740. The stock’s 50-day moving average is GBX 188.20 and its 200-day moving average is GBX 160.85. The company has a debt-to-equity ratio of 5.40, a current ratio of 2.55 and a quick ratio of 9.92. Diaceutics PLC has a 52 week low of GBX 125 and a 52 week high of GBX 210. The stock has a market cap of £164.85 million, a price-to-earnings ratio of -606.25 and a beta of 0.88.

Diaceutics (LON:DXRX) last issued its quarterly earnings data on Tuesday, September 22nd. The company reported GBX (3.27) EPS for the quarter. Diaceutics had a negative return on equity of 0.68% and a negative net margin of 0.66%. As a group, research analysts forecast that Diaceutics PLC will post 1.01 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group restated a “buy” rating and issued a GBX 215 price objective on shares of Diaceutics in a report on Tuesday. Two analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of GBX 215.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.